TLDR
- ARK Invest bought 162,327 CRISPR Therapeutics shares worth $10.06 million through ARKK and ARKG funds on November 4, 2025.
- Cathie Wood’s firm purchased 291,001 Beam Therapeutics shares valued at $7.06 million, focusing on gene-editing technology.
- ARK sold 27,423 Teradyne shares for $5.02 million and 15,362 Roku shares for $1.67 million through its ARKK fund.
- The investment firm trimmed 20,485 SoFi Technologies shares worth $627,455 through its ARKF fintech fund.
- Total gene-editing investments reached $17.12 million while tech sales totaled approximately $7.3 million.
Cathie Wood’s ARK Invest completed a portfolio shift on November 4, 2025, buying biotech stocks while reducing tech positions. The firm’s trading activity focused heavily on gene-editing companies.
ARK purchased 162,327 CRISPR Therapeutics shares for $10.06 million. The buy was split between ARK Innovation ETF and ARK Genomic Revolution ETF.
The firm acquired 291,001 Beam Therapeutics shares worth $7.06 million through the same two funds. This brought total gene-editing investments to over $17 million for the day.
Both companies work on gene-editing treatments for medical conditions. ARK’s purchases show confidence in this growing sector.
ARK added 23,963 Bullish shares valued at $1.20 million across several ETFs. This increased the firm’s exposure to digital asset platforms.
Tech Position Reductions
The investment firm sold 27,423 Teradyne shares worth $5.02 million through ARKK. This extends recent selling in semiconductor testing stocks.
ARK Invest trimmed 15,362 Roku shares for $1.67 million via the ARKK fund. The streaming company has seen multiple position reductions from ARK.
The firm sold 20,485 SoFi Technologies shares valued at $627,455. This transaction went through the ARK Fintech Innovation ETF.
Trading Activity Breakdown
CRISPR Therapeutics received ARK’s largest investment of November 4. The $10.06 million purchase shows strong interest in the gene-editing leader.
Beam Therapeutics got the second-biggest buy at $7.06 million. Both stocks went into ARKK and ARKG portfolios.
The Teradyne sale marked ARK’s biggest reduction for the day. The company has faced selling pressure from ARK in recent trading sessions.
Roku saw continued trimming from ARK’s holdings. The streaming platform stock has been gradually reduced over multiple trades.
SoFi represented a smaller fintech adjustment through ARKF. The sale was part of ARK’s portfolio rebalancing efforts.
ARK’s buying exceeded selling by nearly $10 million on November 4. The firm moved capital from established tech into emerging biotech.
The gene-editing purchases used only ARKK and ARKG funds. These ETFs focus on innovation and genomic revolution investments.
CRISPR and Beam combined for $17.12 million in new positions. This represented the bulk of ARK’s trading volume for the day.
The Bullish purchase added to cryptocurrency-related holdings. This buy was smaller than the biotech investments.
ARK’s pattern shows preference for life sciences over traditional technology. The firm allocated more than twice its sales proceeds into biotech stocks.
Teradyne, Roku, and SoFi sales freed up capital for new investments. ARK used these funds to increase gene-editing exposure.
The November 4 trades reflect ongoing portfolio strategy changes at ARK. The firm continues rotating between sectors based on growth potential.
ARKK handled most of the selling activity across tech stocks. ARKG and ARKK shared the biotech buying equally.
ARK’s gene-editing bets totaled $17.12 million across two companies on November 4, 2025.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
